PT1513525E - Utilização de antagonistas de mglur5 para o tratamento do refluxo gastroesofágico - Google Patents

Utilização de antagonistas de mglur5 para o tratamento do refluxo gastroesofágico Download PDF

Info

Publication number
PT1513525E
PT1513525E PT03731333T PT03731333T PT1513525E PT 1513525 E PT1513525 E PT 1513525E PT 03731333 T PT03731333 T PT 03731333T PT 03731333 T PT03731333 T PT 03731333T PT 1513525 E PT1513525 E PT 1513525E
Authority
PT
Portugal
Prior art keywords
treatment
gerd
antagonists
mglur5 antagonists
glutamate receptor
Prior art date
Application number
PT03731333T
Other languages
English (en)
Portuguese (pt)
Inventor
Anders Lehmann
Jan Mattsson
Thomas M Stormann
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20288301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1513525(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT1513525E publication Critical patent/PT1513525E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT03731333T 2002-06-20 2003-06-19 Utilização de antagonistas de mglur5 para o tratamento do refluxo gastroesofágico PT1513525E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201943A SE0201943D0 (sv) 2002-06-20 2002-06-20 New use

Publications (1)

Publication Number Publication Date
PT1513525E true PT1513525E (pt) 2008-06-24

Family

ID=20288301

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03731333T PT1513525E (pt) 2002-06-20 2003-06-19 Utilização de antagonistas de mglur5 para o tratamento do refluxo gastroesofágico

Country Status (24)

Country Link
EP (1) EP1513525B1 (enExample)
JP (2) JP4683920B2 (enExample)
CN (1) CN100430056C (enExample)
AT (1) ATE395059T1 (enExample)
AU (1) AU2003241585B2 (enExample)
BR (1) BR0311759A (enExample)
CA (1) CA2489730C (enExample)
CY (1) CY1107954T1 (enExample)
DE (1) DE60320990D1 (enExample)
DK (1) DK1513525T3 (enExample)
ES (1) ES2304510T3 (enExample)
IL (1) IL165138A0 (enExample)
IS (1) IS7654A (enExample)
MX (1) MXPA04012659A (enExample)
NO (1) NO20050154L (enExample)
NZ (1) NZ536559A (enExample)
PL (1) PL372186A1 (enExample)
PT (1) PT1513525E (enExample)
RU (1) RU2324484C2 (enExample)
SE (1) SE0201943D0 (enExample)
SI (1) SI1513525T1 (enExample)
UA (1) UA81627C2 (enExample)
WO (1) WO2004000316A1 (enExample)
ZA (1) ZA200409908B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
WO2005060971A1 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
WO2005060961A2 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
WO2005077368A2 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
AU2005214376A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
SG149900A1 (en) * 2004-02-18 2009-02-27 Astrazeneca Ab Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
MX2008012413A (es) * 2006-03-29 2008-10-07 Hoffmann La Roche Derivados de piridina y pirimidina como antagonistas del receptor metabotropico de glutamato 2 (mglur2).
EP2272509A1 (en) 2006-09-11 2011-01-12 Novartis AG New Uses of metabotropic glutamate receptors
JP2008245225A (ja) * 2007-03-29 2008-10-09 Kddi Corp 波長パス経路決定装置、波長パス設定制御システム及びプログラム
WO2009024491A1 (en) * 2007-08-20 2009-02-26 F. Hoffmann-La Roche Ag Use of mglur5 antagonists for the treatment of gerd
WO2010000763A2 (en) 2008-06-30 2010-01-07 Novartis Ag Combination products
EP2456438A2 (en) 2009-07-23 2012-05-30 Novartis AG Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
WO2011048150A1 (en) 2009-10-20 2011-04-28 Novartis Ag Use of 1h-quinazoline-2,4-diones
CA2800970A1 (en) 2010-06-24 2011-12-29 Novartis Ag Use of 1h-quinazoline-2,4-diones
US20140171448A1 (en) 2011-01-27 2014-06-19 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
CA2846503A1 (en) 2011-09-07 2013-03-14 Novartis Ag Use of 1h-quinazoline-2,4-diones for use in the prevention or treatment of photosensitive epilepsy
JP6137336B2 (ja) 2013-01-15 2017-05-31 ノバルティス アーゲー ナルコレプシーの処置のためのアルファ７ニコチン性受容体アゴニストの使用
MX379289B (es) 2013-01-15 2025-03-10 Novartis Ag Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
EP4007575B1 (en) * 2019-11-05 2023-09-27 Claes THULIN 4-[5-[(rac)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4h-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of stress

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004077A1 (en) * 1986-01-03 1987-07-16 The University Of Melbourne Gastro-oesophageal reflux composition
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
JP2002515448A (ja) * 1998-05-15 2002-05-28 アフトン・コーポレーシヨン 食道逆流病の処置法
RU2144331C1 (ru) * 1998-11-05 2000-01-20 Московский НИИ уха, горла и носа Способ лечения хронического гиперпластического ларингита
ATE307129T1 (de) * 1999-08-19 2005-11-15 Nps Pharma Inc Heteropolycyclische verbindungen und ihre verwendung als antagonisten von metabotropen glutamatrezeptoren
CN1703403A (zh) * 2000-10-02 2005-11-30 詹森药业有限公司 趋代谢的谷氨酸盐受体拮抗剂

Also Published As

Publication number Publication date
DK1513525T3 (da) 2008-08-11
MXPA04012659A (es) 2006-05-25
ATE395059T1 (de) 2008-05-15
CY1107954T1 (el) 2013-09-04
RU2324484C2 (ru) 2008-05-20
IS7654A (is) 2005-01-19
SE0201943D0 (sv) 2002-06-20
BR0311759A (pt) 2005-03-08
RU2005101411A (ru) 2005-07-10
AU2003241585A1 (en) 2004-01-06
IL165138A0 (en) 2005-12-18
HK1075833A1 (en) 2005-12-30
PL372186A1 (en) 2005-07-11
NO20050154L (no) 2005-01-11
AU2003241585B2 (en) 2009-06-25
ZA200409908B (en) 2006-08-30
UA81627C2 (ru) 2008-01-25
JP2011068669A (ja) 2011-04-07
EP1513525A1 (en) 2005-03-16
CA2489730C (en) 2011-11-22
NZ536559A (en) 2007-08-31
CA2489730A1 (en) 2003-12-31
DE60320990D1 (de) 2008-06-26
EP1513525B1 (en) 2008-05-14
CN100430056C (zh) 2008-11-05
SI1513525T1 (sl) 2008-08-31
WO2004000316A1 (en) 2003-12-31
JP2006507225A (ja) 2006-03-02
JP4683920B2 (ja) 2011-05-18
CN1662235A (zh) 2005-08-31
ES2304510T3 (es) 2008-10-16

Similar Documents

Publication Publication Date Title
CY1107954T1 (el) Χρηση mglur5 ανταγωνιστων για τηn θεραπεια gerd
WO2005077368A3 (en) Treatment of gastro-esophageal reflux disease (gerd)
DE60205481D1 (de) Furan and thiophen derivate die menschliche peroxisome proliferator aktivierte receptoren aktivieren
NO20020823L (no) Heteropolysykliske forbindelser og deres anvendelse som metabotropiske glutamatreseptorantagonister
IL177394A0 (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP1074549A3 (en) Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors
MY140236A (en) Diarylether compounds useful as opioid receptor antagonists
ATE345128T1 (de) Modulatoren der peroxisom-proliferator- aktivierten rezeptoren (ppar)
MY122020A (en) Use of gabab receptor agonists as reflux inhibitors
ITMI20021620A1 (it) Composto ad ativita' antitumorale
TW200621752A (en) Pyrimidinylpyrazoles and methods of making and using the same
MXPA05009988A (es) Derivados de 6-sulfonamida quinolina y cromeno como antagonistas de los receptores de androgenos.
ATE399175T1 (de) Hemmstoffe der urokinase, ihre herstellung und verwendung
WO2003043619A8 (en) New use for the treatment of gastroesophageal reflux disease
BR0000486A (pt) Antagonistas do neuropeptìdeo y
PE20020052A1 (es) Derivados de sulfonamidas util para potenciar la funcion del receptor de glutamato
TW200700067A (en) Substituted aryl 1,4-pyrazine derivatives
SE0303492D0 (sv) New use VII
WO2005060961A3 (en) Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
SE0303491D0 (sv) New use VI
DE69922918D1 (de) Neuropeptid Y Antagonisten
SE0303490D0 (sv) New use V
TW200626565A (en) Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
HK1094159A (en) Use of metabotropic glutamate receptor 5 (mglur5) antagonists for the treatment of gastrointestinal disorders